Search - tctmd.com

Displaying 201 - 220 of 563

Sort: Relevancy | Date

High-Sensitivity Troponin Test Predicts Poor Outcomes in Stable Patients With Chest Pain

News Daily News

High-Sensitivity Troponin Test Predicts Poor Outcomes in Stable Patients With Chest Pain

January 22, 2019

CAD Yes, Symptoms No: More Evidence Needed to Guide Care

News Daily News

CAD Yes, Symptoms No: More Evidence Needed to Guide Care

January 16, 2019

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

News Daily News

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

Michael O'Riordan

January 11, 2019

Many PCI Patients Treated in China Have No Angina Symptoms

News Daily News

Many PCI Patients Treated in China Have No Angina Symptoms

December 20, 2018

CTA an Effective Gatekeeper in Invasive Angiography Candidates With Suspected CAD

News Daily News

CTA an Effective Gatekeeper in Invasive Angiography Candidates With Suspected CAD

December 14, 2018

US and European DAPT Guidelines More Alike Than Different, Say Experts

News Daily News

US and European DAPT Guidelines More Alike Than Different, Say Experts

Yael L. Maxwell

December 03, 2018

High-Sensitivity Troponin Assays May Help Cut Down on Unnecessary Stress Tests, Study Suggests

News Daily News

High-Sensitivity Troponin Assays May Help Cut Down on Unnecessary Stress Tests, Study Suggests

November 05, 2018

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

News Daily News

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Yael L. Maxwell

October 30, 2018

Coronary CTA for Suspected CAD Shows Advantages in Predicting Hard Outcomes Over 10 Years

News Daily News

Coronary CTA for Suspected CAD Shows Advantages in Predicting Hard Outcomes Over 10 Years

Yael L. Maxwell

October 23, 2018

Post-MI Beta-blocker Use Dropped During Metoprolol ER Shortage, but Outcomes Unaffected

News Daily News

Post-MI Beta-blocker Use Dropped During Metoprolol ER Shortage, but Outcomes Unaffected

October 15, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

FFR Values Linked to Quality-of-Life Improvement After PCI in Stable CAD Patients

News Daily News

FFR Values Linked to Quality-of-Life Improvement After PCI in Stable CAD Patients

September 21, 2018

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

News Daily News

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Michael O'Riordan

August 23, 2018

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

August 13, 2018

TCTMD’s Top 10 Most Popular Stories for July 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2018

August 01, 2018

SCAI Updates Statement on Intracoronary Diagnostic Tools

News Daily News

SCAI Updates Statement on Intracoronary Diagnostic Tools

July 17, 2018

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

Once Again, ISCHEMIA Trial Feels the Squeeze

News Daily News

Once Again, ISCHEMIA Trial Feels the Squeeze

Michael O'Riordan

June 29, 2018

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.